Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.

Across all BMI groups for both treatments, SS trough IgG concentrations ≥ 7 g/L were maintained for all patients. Pharmacokinetic Simulations for Age Groups The PK simulations of SCIG and fSCIG treatments showed a trend for lower serum IgG levels with decreasing age (Fig. 2 ); however, the 90% confidence interval for the adult simulations encompassed the majority of the simulated exposures for the pediatric groups.

also in 53,322 other papers